Last reviewed 2026-04-19 · How we verify

rF1 and rV protein antigens

PharmAthene UK Limited · Phase 1 active Biologic

rF1 and rV protein antigens is a Biologic drug developed by PharmAthene UK Limited. It is currently in Phase 1 development.

At a glance

Generic name	rF1 and rV protein antigens
Sponsor	PharmAthene UK Limited
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

rF1 and rV protein antigens CI brief — competitive landscape report
rF1 and rV protein antigens updates RSS · CI watch RSS
PharmAthene UK Limited portfolio CI

Frequently asked questions about rF1 and rV protein antigens

What is rF1 and rV protein antigens?

rF1 and rV protein antigens is a Biologic drug developed by PharmAthene UK Limited.

Who makes rF1 and rV protein antigens?

rF1 and rV protein antigens is developed by PharmAthene UK Limited (see full PharmAthene UK Limited pipeline at /company/pharmathene-uk-limited).

What development phase is rF1 and rV protein antigens in?

rF1 and rV protein antigens is in Phase 1.

Manufacturer: PharmAthene UK Limited — full pipeline
Compare: rF1 and rV protein antigens vs similar drugs
Pricing: rF1 and rV protein antigens cost, discount & access